Based on the Citius Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Citius Pharmaceuticals Inc is not available over the next 12 months. Citius Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Citius Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Citius Pharmaceuticals Inc’s stock price was USD 1.05. Citius Pharmaceuticals Inc’s stock price has changed by -11.02% over the past week, -41.34% over the past month and -95.28% over the last year.
No recent analyst target price found for Citius Pharmaceuticals Inc
No recent average analyst rating found for Citius Pharmaceuticals Inc
Company Overview Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Read Less
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeli...Read More
Frequently Asked Questions About Citius Pharmaceuticals Inc (CTXR) Stock
Stock Target Advisor's fundamental analysis for Citius Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on CTXR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CTXR's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CTXR's stock to indicate if its overvalued.
The last closing price of CTXR's stock was USD 1.05.
The most recent market capitalization for CTXR is USD 9.19M.
Unfortunately we do not have enough analyst data on CTXR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Citius Pharmaceuticals Inc's stock.
As per our most recent records Citius Pharmaceuticals Inc has 23 Employees.
Citius Pharmaceuticals Inc's registered address is 11 Commerce Drive, Cranford, NJ, United States, 07016.
You can get more information about it from Citius Pharmaceuticals Inc's website at https://citiuspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Citius Pharmaceuticals Inc (CTXR) Stock
Stock Target Advisor's fundamental analysis for Citius Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on CTXR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CTXR's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CTXR's stock to indicate if its overvalued.
The last closing price of CTXR's stock was USD 1.05.
The most recent market capitalization for CTXR is USD 9.19M.
Unfortunately we do not have enough analyst data on CTXR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Citius Pharmaceuticals Inc's stock.
As per our most recent records Citius Pharmaceuticals Inc has 23 Employees.
Citius Pharmaceuticals Inc's registered address is 11 Commerce Drive, Cranford, NJ, United States, 07016.
You can get more information about it from Citius Pharmaceuticals Inc's website at https://citiuspharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CTXR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
